The FDA approved a supplemental application to NDA 202429, Zelboraf (vemurafenib), held by Hoffmann-La Roche, on 20 August 2026.
That is the whole of what the enforcement record states. A supplemental new drug application can carry a new indication, a change to the labelled dosing or safety information, a new manufacturing site, or a packaging change, and the approvals database entry does not distinguish them. So the accurate statement to a colleague is that the application was amended and approved, and that what changed has to be read from the Drugs@FDA entry itself before it means anything clinically.
What it is not is a new approval of vemurafenib, which has been licensed for BRAF V600E-mutant melanoma since 2011 and for Erdheim-Chester disease since 2017. Nothing here alters current prescribing, and nothing here should be relayed to a patient as a change to their treatment. In India, vemurafenib's availability and cost remain the practical constraint on its use rather than its regulatory status, and a US supplemental approval has no bearing on the CDSCO position.
- Read the Drugs@FDA entry before acting on a supplemental approval — the record does not say what changed.
- Do not describe this as a new approval or a new indication; neither is established by the record.
- Vemurafenib's licensed indications remain BRAF V600E-mutant melanoma and Erdheim-Chester disease.
- A US supplemental approval says nothing about CDSCO status or Indian availability.
- Where a label change does land, the parts that reach the clinic are usually dosing, monitoring and interactions.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free